Open access
Open access
Powered by Google Translator Translator

RCT | Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause

23 Mar, 2023 | 13:01h | UTC

Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study – The Lancet (link to abstract – $ for full-text)

Related: Efficacy and Safety of Fezolinetant in Moderate-to-Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT – The Journal of Clinical Endocrinology & Metabolism

 

Commentary on Twitter (thread – click for more)

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.